As therapy for chronic lymphocytic leukemia (CLL) continues to evolve, 2025 brought research, regulatory news, and expert ...
Covalent Bruton tyrosine kinase inhibitors (BTKis) have improved CLL management, but discontinuation due to adverse events ...
TipRanks on MSN
AbbVie’s venetoclax study completion: Implications for CLL treatment and market dynamics
Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie has recently completed a clinical study titled ...
Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.
A recent study reveals promising results for CLL patients using zanubrutinib and venetoclax, highlighting effective ...
Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) are types of slow-growing cancers that affect a type of white blood cell called a lymphocyte. Lymphocytes are cells that help ...
MedPage Today on MSN
Fixed-duration or continuous therapy in CLL: Trial says take your pick
The aim of the fixed-duration approach is to "produce deep remissions and thereby allow patients to get off therapy while still remaining in remission -- and so having multiple years ideally of ...
"Second Winds" refers to how diagnosis and treatment of CLL can lead to "fulfilling lives," says Abbvie's Matt Skryja.
Join Dr Krish Patel and discover groundbreaking updates in lymphoma and CLL treatments, including innovative therapies and ...
The cancer diagnosis is not a full stop. "Second Winds" profiles CLL patients Christina Fisher, Alejandro Daza, and Jeff Mesky, sharing their journey to thrive. Watch the documentary.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback